Simulations Plus, Inc.

NASDAQ:SLP

Medical - Healthcare Information Services

Healthcare
$18.50 +0.11%

+$0.02 today

Market cap
$374.16M
Beta
1.32
P/E (TTM)
-5.9
EPS (TTM)
-$3.12
52W Low $11.09High $21.01

Volume 0.00M

Average 0.35M

SLP Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Simulations Plus, Inc.NASDAQ: SLP

Stock-Based Compensation · Q2 FY2026 · quarter ended Feb 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $1.62M fell 4.1% year over year, ahead of the -7.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +27.9% a year.

Context

  • Stock-based compensation amounted to 8.0% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -4.1% holds above the trailing-twelve-month pace of -7.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterFeb 2026
$1.62M+0.5% QoQ
Last fiscal yearAug 2025
$6.35M-2.8% YoY
LTMFeb 2026
$6.18M-7.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.1%——
1 year-2.8%——
3-year CAGR+27.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.35M USD
Year-over-year change
-2.8%
4-year CAGR
+23.3%

Stock-Based Compensation vs competitors

How SLP compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.5% is the 4th highest of 11, against a peer median of -16.9%.
  • Stock-based compensation amounts to 7.7% of revenue for SLP, versus a peer median of 10.5%.
SLP Competitors
Stock-Based Compensation for SLP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGLAgilon Health, Inc.LTM Mar 2026$38.65M USD-23.4%+20.1%0.7%
DHDefinitive Healthcare Corp.LTM Mar 2026$27.05M USD-9.3%-7.2%11.4%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$8.5M USD-48.8%—10.5%
OPRXOptimizeRx CorporationLTM Mar 2026$7.23M USD-27.7%-23.8%6.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
SLPSimulations Plus, Inc.LTM Feb 2026$6.18M USD-7.5%+27.9%7.7%
KRROKorro Bio, Inc.LTM Mar 2026$4.8M USD-10.4%+88.7%125.0%
NRCNational Research CorporationLTM Mar 2026$4.75M USD+867.2%+40.3%3.4%
NAKANakamoto Inc.LTM Mar 2026$3.96M USD+43865.8%+2.1%101.0%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
Peer median (excluding SLP) —-16.9%+20.1%10.5%

Competitors are the stored peer set for SLP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Aug 2023
FY2024
Aug 2024
FY2025
Aug 2025
Net Income9.78M12.48M9.96M9.95M(64.72M)
Depreciation & Amortization3.59M3.57M3.84M5.67M8.21M
Deferred Income Tax(628K)(270K)(2.1M)(1.77M)(5.43M)
Stock-Based Compensation2.75M3.04M4.83M6.54M6.35M
Change in Working Capital974K(2.62M)5.1M(4.21M)(2.59M)
Accounts Receivables(2.43M)(3.94M)4.1M3.13M(581K)
Inventory3.15M0000
Accounts Payables39K(162K)(81K)(477K)(132K)
Other Working Capital210K1.48M1.09M(6.86M)(1.87M)
Other Non-Cash Items2.74M1.7M219K(2.86M)76.29M
Operating Cash Flow19.2M17.9M21.86M13.32M18.13M
Capital Expenditures(4.58M)(3.97M)(4.27M)(566K)(713K)
Acquisitions (Net)2.95M3.15M(8.22M)(98.77M)0
Purchases of Investments(122.4M)(100.85M)(95.05M)(67.16M)(6.5M)
Sales of Investments100.23M109.12M114.91M116.27M15.01M
Other Investing Activities(2.95M)(3.15M)(3.82M)(3.74M)(4.24M)
Investing Cash Flow(26.74M)4.31M7.37M(53.97M)3.56M
Debt Repayment00000
Common Stock Issued1.46M891K0731K430K
Common Stock Repurchased00(20M)00
Dividends Paid(4.81M)(4.85M)(4.81M)(4.8M)0
Other Financing Activities(1.33M)(3.67M)1.54M(2.5M)(1.58M)
Financing Cash Flow(4.68M)(7.62M)(23.27M)(6.57M)(1.15M)
Effect of Forex Changes00000
Net Change in Cash(12.22M)14.58M5.96M(47.21M)20.54M
Free Cash Flow14.63M13.93M17.58M12.75M17.41M

Simulations Plus, Inc.

NASDAQ:SLP

Intrinsic Alpha fair value

Locked

Current Price

$18.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.